Nike ( NKE) was upgraded at Argus to buy from hold. $84 price target. Company is raising prices and should continue to gain market share, Argus said.

OneBeacon Insurance ( OB) was upgraded to buy at TheStreet Ratings.

Regal Entertainment ( RGC) was upgraded to buy at TheStreet Ratings.

Public Service ( PEG) was upgraded at Deutsche Bank to buy from hold. Valuation call, based on a $37 price target, Deutsche Bank said.

Torchmark ( TMK) was downgraded at FBR Capital Markets to market perform from outperform. $69 price target. Valuation call, as the company could face continued sales challenges, FBR Capital Markets said.

T-Mobile US ( TMUS) was upgraded at Oppenheimer to outperform from perform. $32 price target. Expect better churn trajectory and cost savings, Oppenheimer said.

Under Armour ( UA) was upgraded at J.P. Morgan to neutral from underweight. $77 price target. Top-line prospects have improved, J.P. Morgan said.

Valmont ( VMI) was downgraded at Stifel Nicolaus to hold from buy. Company may struggle to maintain its growth rate, Stifel Nicolaus said.


Citigroup ( C) estimates, price target were raised at Credit Suisse. Shares are now seen reaching $65. Estimates were also increased, given continued expected international growth, Credit Suisse said. Outperform rating.

Chipotle Mexican Grill ( CMG) numbers were increased at Jefferies. Shares are now seen reaching $410. Estimates were also increased as marketing efforts helped maintain momentum through the third quarter, Jefferies said. Hold rating.

Dow Chemical ( DOW) numbers were boosted at UBS. Shares are now seen reaching $43. Estimates were also increased, given higher expected growth, UBS said. Buy rating.

Microsoft ( MSFT) estimates, price target were reduced at UBS. Shares are now seen reaching $37. Estimates were also cut, given lower expected margins, UBS said. Buy rating.

Nike price target was increased at J.P. Morgan to $80. Remains best in class with top line growth and margin drivers, J.P. Morgan said. Overweight rating.

Yum! Brands ( YUM) estimates were lowered at Jefferies through 2014. Downside risk remains given competitive intrusion, Jefferies said. Hold rating.

>To submit a news tip, email:

Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

What a Difference a Day Makes for New SEC Rule

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis